KDR and nonpapillary renal cell carcinoma: Thus, inhibitors that target VEGFR, which include sorafenib, sunitinib, pazopanib, axitinib, and lenvatinib, are thought to be effective options with ccRCC patients and in recent years, their combination with IO agents has been established as the standard of care for first-line treatment [10].